13 RESULTS
COMMENT This report should be supported by the pathogenic confirmation of Alzheimer’s disease, but it is still a very attractive observation for the Alzheimer’s field. Currently, it is popular to clarify the pathogenic mechanisms that induce MCI or early ...
COMMENT Yes, aging is the strongest risk factor, but how does age induce Alzheimer's disease? We have found that age suppresses excretion of homocysteic acid (HA) into urine, which, we believe, induces Alzheimer's disease (1). We reported that HA is a ...
COMMENT Yes, this is a very nice, suggestive paper. It is especially interesting that DHA has no effect of amyloid-β and tau levels, yet improved memory performance. Our previous paper reported that this mouse model showed higher levels of pathogenic homocysteic ...
COMMENT It is always my pleasure to read such a wonderful paper. However, I always wonder why the clinical trials of amyloid treatment fail. Amyloid itself shows toxicity in Alzheimer’s model mice, but in the case of humans, amyloid itself does not show any ...
COMMENT Drs. Raichle and Mintun have reported a very interesting phenomenon, that is, amyloid deposition is related to aerobic glycolysis. But they have not clarified the reason why amyloid preferably deposits in the glycolysis portions of brain. I'd like to ...
COMMENT A surprising report has been published in PLoS ONE (1). Amyloid-β is now thought to be an antimicrobial peptide. If this report is right, the present amyloid treatment strategies are completely wrong and should be stopped to develop new ones. The amyloid ...
COMMENT A Chinese article (1) has previously reported that homocysteic acid (HA) levels in blood were higher in cerebral infarction with dementia than in cerebral infarction without dementia. The article also reported that HA levels increased in parallel with the ...
COMMENT Recently, JAMA (1) reported that the Phase 3 clinical trial of Tarenflurbil, aka flurizan, a γ-secretase modulator, has failed, which confirms that one would consider that the amyloid hypothesis is no longer valid, or, that targeting amyloid is not ...
COMMENT Tarenflurbil, a γ-secretase modulator, failed in Phase 3 trial. Recent clinical failures of amyloid treatment including tarenflurbil have brought confusion to the Alzheimer’s field, which should consider the pathogenic differences of amyloid between ...
COMMENT Dr. Saura discussed that FAD presenilin mutation showed neurodegeneration in humans, but not in mice. Why this difference? We believe that homocysteic acid (HA) may be a pathogenic compound for Alzheimer disease. In our hands, HA induced neurodegeneration ...
COMMENT The authors have observed an interesting pathogenic change in the 3xTg-AD female brain in that a mitochondrial deficit preceded the amyloid pathology. I agree with their observations, and have this question: What induced the mitochondrial impairment? Our ...
COMMENT Our findings in B6-deficient diet are based on the controversial situation of homocysteine risk factor for Alzheimer disease. The New England Journal of Medicine reported that administration of vitamin B6, folic acid and vitamin B12 to older persons did ...
COMMENT It is known that homocysteine is a risk factor for Alzheimer disease, but recently it has been reported that treatment to lower homocysteine had no effect for Alzheimer dementia, which suggests two possible explanations. One is that homocysteine's ...
